WGSGeneDx Holdings Corp.

Healthcare

$67.31-48% 1Y

$67.31

$34.5152 weeks$167.51

Price

-48%1Y

End-of-day closes, not the intraday tick.

A mixed picture: the questions disagree

Quality mixed, nothing alarming, growth steady, the market against it.

RyuScore 27 of 100: see how it is built

What they do

The genome is composed of 3 billion “letters”, or base pairs, of DNA. The exome is a portion of the genome that encodes proteins, which are involved in many different types of cellular functions. Changes in DNA can change the way proteins are formed or utilized by the cell, potentially causing disease. When patients present with complex issues, a genetic diagnosis may be available, but a traditional genetic panel test may be too narrow to identify the cause.

In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR

P/En/a

Market value$2.04B

1 year-48%

5 years-77%

Charts

As reported to the SEC, without any scoring.

GeneDx Holdings Corp. (WGS) reported revenue of $114M in Q2 2026 (quarter ended Jun 30, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 68% and net loss of $18M. For the full year FY2025, revenue was $428M (+40% year on year) and net income −$21M. Its largest product in Q2 2026 was Diagnostic Test Third Party Insurance at $95M, 83% of the disclosed total, well ahead of Diagnostic Test Institutional Customers at 14%. The next results filing is expected around Oct 27, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

Aug 3, 2026GeneDx Reports Second Quarter 2026 Financial Results.Earnings release · press release
Jun 16, 2026On June 16, 2026, GeneDx Holdings Corp. (the “Company”) announced the appointment of Mark Gardner, age 60, in the role of President, which was effective on June 15, 2026.Director or officer change · Form 8-K
May 4, 2026GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook.Earnings release · press release